

Copper-catalyzed asymmetric construction of dispiropyrrolidine skeleton via 1,3-dipolar cycloaddition of azomethine ylides with α -alkylidene succinimides

Wu-Lin Yang,^a Yang-Zi Liu,^a Shuai Luo,^a Xingxin Yu,^{*a} John S. Fossey^b and Wei-Ping Deng^{*a}

^a Shanghai Key Laboratory of New Drug Design & School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai, 200237, China

^b School of Chemistry, University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT, UK

Contents

- 1. General information**
- 2. Table S1. Optimization of the asymmetric 1,3-dipolar cycloaddition of azomethine ylide 1a to α -alkylidene succinimide 2b**
- 3. Procedure for synthesis of α -alkylidene succinimides**
- 4. Procedure for asymmetric 1,3-dipolar cycloaddition of azomethine ylides to α -alkylidene succinimides**
- 5. Scheme S1. Scaled up asymmetric 1,3-dipolar cycloaddition of azomethine ylide 1f to α -alkylidene succinimide 2b**
- 6. Synthetic transformations of the cycloadduct**
- 7. The absolute configuration determination of (1*R*,3*R*,4*R*,5*R*)-6**
- 8. Scheme S2. Proposed transition state leading to the major product *endo*-3ab**
- 9. Procedure for asymmetric 1,3-dipolar cycloaddition of azomethine ylides to 2-oxoindolin-3-ylidenes**
- 10. References**
- 11. HPLC Chromatograms**
- 12. ^1H NMR and ^{13}C NMR spectra of products**

General information

¹H NMR spectrum were recorded on a Bruker DPX 400 MHz spectrometer in CDCl₃ or (CD₃)₂SO. Chemical shifts were reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The spectrum are interpreted as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, brs = broad singlet, coupling constant(s) *J* are reported in Hz and relative integrations are reported. ¹³C NMR (100 MHz) spectrum were recorded on a Bruker DPX 400 MHz spectrometer in CDCl₃ or (CD₃)₂SO. Chemical shifts were reported in ppm with the internal chloroform signal at 77.16 ppm or DMSO signal at 39.52 ppm as a standard. Optical rotations were measured on an AUTOPOL V. Diastereomeric ratios were determined from crude ¹H NMR spectroscopy interpretation. Enantiomeric excess were determined by analysis of HPLC traces, obtained by using chiralcel AD-H, AS-H, or IF columns with *n*-hexane and *i*-propanol or EtOAc as solvents. (Chiralcel AD-H, AS-H, and IF columns were purchased from Daicel Chemical Industries, LTD.) Melting points were obtained in open capillary tubes using SGW X-4 micro melting point apparatus which were uncorrected. Mass spectrum were recorded on TOF mass spectrometer. All reagents and starting materials were obtained commercially and used as received unless otherwise stated. Toluene, THF, CPME, 1,4-dioxane and MeTHF were distilled over sodium/benzophenone. CH₃CN, CH₂Cl₂ and EtOAc were distilled over calcium hydride.


Table S1. Optimization of the asymmetric 1,3-dipolar cycloaddition of azomethine ylide **1a to α -alkylidene succinimide **2b****

Entry ^a	Base (mol%)	Solvent	T (°C)	Yield (%) ^b	ee (%) ^c
1	K ₂ CO ₃ (2 equiv.)	THF	RT	85	93
2	Et ₃ N (20)	THF	RT	50	93
3	KO'Bu (10)	THF	RT	78	93
4	Cs ₂ CO ₃ (20)	THF	RT	80	93
5	NaHMDS (10)	THF	RT	82	93
6	K ₂ CO ₃ (2 equiv.)	CH ₂ Cl ₂	RT	trace	-
7	K ₂ CO ₃ (2 equiv.)	EtOAc	RT	32	91
8	K ₂ CO ₃ (2 equiv.)	toluene	RT	68	95
9	K ₂ CO ₃ (2 equiv.)	1,4-dioxane	RT	trace	-
10	K ₂ CO ₃ (2 equiv.)	CH ₃ CN	RT	63	81

11	K_2CO_3 (2 equiv.)	MeTHF	RT	85	95
12 ^d	K_2CO_3 (2 equiv.)	MeTHF	RT	85	95


^a All reactions were carried out with 0.2 mmol of **1a** and 0.1 mmol of **2a** in 1 mL of solvent. MeTHF = 2-Methyltetrahydrofuran. ^b Isolated yield. ^c Determined by chiral HPLC analysis, and >20:1 dr was determined by ¹H NMR of crude product. ^d 5 mol% catalyst was used

Procedure for the synthesis of α -alkylidene succinimides¹⁻³




A maleimide derivative (10 mmol, 1.0 equiv.), corresponding aldehyde (10 mmol, 1.0 equiv.) and triphenylphosphine (10 mmol, 1.0 equiv.), were dissolved in anhydrous CH_2Cl_2 (30 mL) and stirred at room temperature for 24 h. The solvent was removed *in vacuo* and purification of the crude product by flash column chromatography yielded the α -alkylidene succinimides **2**.


(E)-3-Benzylidenepyrrolidine-2,5-dione (2a). White solid, yield (75%), m.p: > 200 °C; ¹H NMR




Methyl (E)-3-benzylidene-2,5-dioxopyrrolidine-1-carboxylate (2b). White solid, yield (72%),



Benzyl (E)-3-benzylidene-2,5-dioxopyrrolidine-1-carboxylate (2c). White solid, yield (80%),




Methyl (E)-3-(4-methoxybenzylidene)-2,5-dioxopyrrolidine-1-carboxylate (2d). White solid,



yield (67%), m.p: 155-157 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, *J* = 1.9, 1H), 7.51-7.40 (m, 2H), 7.06-6.92 (m, 2H), 4.03 (d, *J* = 2.0, 3H), 3.87 (d, *J* = 1.9, 3H), 3.65 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.0, 166.8, 161.7, 149.1, 137.1,


132.5, 126.4, 118.5, 114.8, 55.5, 54.9, 34.5; HRMS (EI, m/z): Calcd for C₁₄H₁₃NO₅ [M]⁺: 275.0789, found: 275.0789.

Methyl (E)-2,5-dioxo-3-(4-(trifluoromethyl)benzylidene)pyrrolidine-1-carboxylate (2e). White



solid, yield (70%), m.p: 200-202 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.76-7.78 (m, 2H), 7.73 (s, 1H), 7.62 (d, *J* = 8.2, 2H), 4.04 (s, 3H), 3.73 (d, *J* = 2.4, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 169.1, 166.1, 148.8, 136.8, 135.4, 132.1 (q, *J*_{C-F} = 32.9), 130.5, 126.2 (q, *J*_{C-F} = 3.7), 124.2, 123.6 (q, *J*_{C-F} = 272.4), 55.1, 34.3; HRMS (EI, m/z): Calcd for C₁₄H₁₀F₃NO₄ [M]⁺: 313.0557, found: 313.0560.


Methyl (E)-3-(4-bromobenzylidene)-2,5-dioxopyrrolidine-1-carboxylate (2f). White solid,



yield (63%), m.p: 193-195 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.71-7.68 (m, 1H), 7.64 (d, *J* = 8.4, 2H), 7.38 (d, *J* = 8.4, 2H), 4.05 (s, 3H), 3.68 (d, *J* = 2.3, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 169.3, 166.3, 148.9, 136.0, 132.6, 132.4, 131.7, 125.5, 122.2, 55.1, 34.3; HRMS (EI, m/z): Calcd for C₁₃H₁₀BrNO₄ [M]⁺:

322.9788, found: 322.9794.


Methyl (E)-3-(3-bromobenzylidene)-2,5-dioxopyrrolidine-1-carboxylate (2g). White solid,



yield (65%), m.p: 160-162 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.66-7.67 (m, 1H), 7.62 (s, 1H), 7.59 (d, *J* = 7.9, 1H), 7.43 (d, *J* = 7.8, 1H), 7.36 (t, *J* = 7.8, 1H), 4.03 (s, 3H), 3.70 (d, *J* = 2.4, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 169.3, 166.2, 148.9, 135.6, 135.5, 133.7, 133.0, 130.7, 128.9, 123.3, 123.1, 55.1, 34.3; HRMS (EI, m/z):

Calcd for C₁₃H₁₀BrNO₄ [M]⁺: 322.9788, found: 322.9792.


Methyl (E)-3-(furan-2-ylmethylene)-2,5-dioxopyrrolidine-1-carboxylate (2h). Yellow solid,



yield (75%), m.p: 141-143 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, *J* = 1.4, 1H), 7.48 (t, *J* = 2.4, 1H), 6.81 (d, *J* = 3.5, 1H), 6.58 (dd, *J* = 3.5, 1.8, 1H), 4.02 (s, 3H), 3.75 (d, *J* = 2.4, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.2, 166.3, 150.6, 149.1, 146.6, 123.0, 118.7,


118.4, 113.0, 54.9, 34.5; HRMS (EI, m/z): Calcd for C₁₁H₉NO₅ [M]⁺: 235.0476, found: 235.0480.

Methyl (E)-3-butylidene-2,5-dioxopyrrolidine-1-carboxylate (2i).



Colorless oil, yield (68%), ^1H NMR (400 MHz, CDCl_3) δ 7.02-6.92 (m, 1H), 4.00 (s, 3H), 3.34 (dt, J = 2.6, 1.4, 2H), 2.20 (q, J = 7.4, 2H), 1.65-1.49 (m, 2H), 0.97 (t, J = 7.4, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.8, 165.3, 149.0, 142.6, 124.2, 54.9, 32.3, 32.1, 21.3, 13.8; HRMS (EI, m/z): Calcd for $\text{C}_{10}\text{H}_{13}\text{NO}_4$ [M] $^+$: 211.0840, found: 211.0843.


Methyl (*E*)-2,5-dioxo-3-((*E*)-3-phenylallylidene)pyrrolidine-1-carboxylate(2j). Yellow solid,




yield (70%), m.p: 196-198 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.49 (m, 3H), 7.43-7.34 (m, 3H), 7.08 (d, J = 15.4, 1H), 6.78 (dd, J = 15.4, 11.7, 1H), 4.02 (s, 3H), 3.53 (d, J = 2.2, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.6, 165.8, 149.1, 144.3, 137.0, 135.4, 130.1, 129.0, 127.7, 122.5, 121.9, 54.9, 32.8;

HRMS (EI, m/z): Calcd for $\text{C}_{15}\text{H}_{13}\text{NO}_4$ [M] $^+$: 271.0840, found: 271.0847.

Procedure for the asymmetric 1,3-dipolar cycloaddition of azomethine ylides to α -alkyldene succinimides




Under a nitrogen atmosphere, $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (2.0 mg, 0.01 mmol), ligand **4a** (4.4 mg, 0.011 mmol), K_2CO_3 (55.3 mg, 0.4 mmol) and 4 Å MS were dissolved in MeTHF (2 mL), and stirred at room temperature for approximately 1 h. Then, iminoester **1** (0.4 mmol) and α -alkyldene succinimides **2** (0.2 mmol) were added sequentially. Once starting material was consumed (monitored by TLC), the mixture was concentrated and purified by column chromatography to give the corresponding cycloaddition product.



Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(4-chlorophenyl)-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-


2,8-dicarboxylate

Yield (88%); White solid, m.p: 82-84 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.40 (m, 2H), 7.37-7.32 (m, 3H), 7.29-7.24 (m, 4H), 4.45 (s, 1H), 4.28 (d, *J* = 5.7, 1H), 4.08 (d, *J* = 5.7, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 2.47 (d, *J* = 18.7, 1H), 2.30 (d, *J* = 18.7, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 175.2, 172.3, 169.6, 147.6, 139.0, 135.2, 133.1, 129.5, 129.3, 128.6, 128.3, 128.0, 73.7, 67.1, 60.2, 54.9, 54.7, 52.7, 37.3; HRMS (EI, m/z): Calcd for C₂₃H₂₁ClN₂O₆ [M]⁺: 456.1083, found: 456.1091; [α]_D²⁵ = +52.9 (*c* 1.58, CH₂Cl₂); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) t_R = 21.23 min, 34.28 min.




8-Ethyl 2-methyl (5*R*,6*R*,8*R*,9*R*)-6-(4-chlorophenyl)-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (72%); White solid, m.p: 36-38 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.40 (m, 2H), 7.37-7.32 (m, 3H), 7.29-7.24 (m, 4H), 4.45 (s, 1H), 4.36-4.19 (m, 3H), 4.06 (d, *J* = 5.9, 1H), 3.77 (s, 3H), 2.49 (d, *J* = 18.6, 1H), 2.32 (d, *J* = 18.7, 1H), 1.26 (t, *J* = 7.1, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 175.1, 171.8, 169.7, 147.6, 139.0, 135.2, 133.1, 129.5, 129.3, 128.6, 128.2, 128.0, 73.9, 67.3, 61.7, 60.2, 55.2, 54.8, 37.4, 14.2; HRMS (EI, m/z): Calcd for C₂₄H₂₃ClN₂O₆ [M]⁺: 470.1240, found: 470.1252; [α]_D²⁵ = +58.7 (*c* 1.13, CH₂Cl₂); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) t_R = 18.57 min, 38.30 min.




Dimethyl (5*R*,6*R*,8*R*,9*R*)-1,3-dioxo-6,9-diphenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (83%); White solid, m.p: 60-62 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.40 (m, 2H), 7.37-7.31 (m, 6H), 7.27-7.25 (m, 2H), 4.46 (s, 1H), 4.29 (d, *J* = 5.6, 1H), 4.07 (d, *J* = 5.7, 1H), 3.82 (s, 3H), 3.73 (s, 3H), 2.46 (d, *J* = 18.6, 1H), 2.33 (d, *J* = 18.7, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 175.5, 172.4, 169.8, 147.7, 139.3, 134.1, 129.5, 129.3, 129.2, 128.6, 128.2, 126.5, 74.5, 67.5, 60.2, 55.3, 54.5, 52.7, 37.3; HRMS (EI, m/z): Calcd for C₂₃H₂₂N₂O₆ [M]⁺: 422.1473, found: 422.1476; [α]_D²⁵ = +56.2 (*c* 1.22, CH₂Cl₂); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) t_R = 19.09 min, 29.40 min.




Dimethyl (5*R*,6*S*,8*R*,9*R*)-6-(2-chlorophenyl)-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (81%); White solid, m.p: 60-62 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.74 (dd, $J = 7.7, 1.4$ Hz, 1H), 7.43-7.30 (m, 5H), 7.29-7.22 (m, 3H), 5.20 (s, 1H), 4.35 (d, $J = 7.8$, 1H), 4.15 (d, $J = 7.8$, 1H), 3.78 (s, 6H), 2.84 (d, $J = 18.5$, 1H), 2.53 (d, $J = 18.5$, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.6, 172.3, 169.8, 147.9, 137.1, 134.0, 133.3, 129.9, 129.8, 129.4, 128.7, 128.6, 128.3, 127.5, 68.2, 65.3, 60.7, 54.7, 54.6, 52.6, 37.56; HRMS (EI, m/z): Calcd for $\text{C}_{23}\text{H}_{21}\text{ClN}_2\text{O}_6$ [M] $^+$: 456.1083, found: 456.1088; $[\alpha]_D^{25} = +32.3$ (c 1.22, CH_2Cl_2); HPLC (Chiralcel AD-H, hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 17.16$ min, 22.63 min.



Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(3-chlorophenyl)-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate


Yield (80%); White solid, m.p: 124-126 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.44-7.40 (m, 2H), 7.37-7.29 (m, 3H), 7.27-7.24 (m, 3H), 7.22-7.19 (m, $J = 7.5$ Hz, 1H), 4.43 (s, 1H), 4.29 (d, $J = 5.7$ Hz, 1H), 4.08 (d, $J = 5.7$ Hz, 1H), 3.82 (s, 3H), 3.79 (s, 3H), 2.48 (d, $J = 18.6$ Hz, 1H), 2.30 (d, $J = 18.7$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.1, 172.2, 169.5, 147.7, 139.0, 136.6, 135.3, 130.4, 129.5, 129.5, 128.6, 128.3, 126.8, 125.1, 73.7, 67.1, 60.1, 54.8, 54.7, 52.7, 37.2; HRMS (EI, m/z): Calcd for $\text{C}_{23}\text{H}_{21}\text{ClN}_2\text{O}_6$ [M] $^+$: 456.1083, found: 456.1083; $[\alpha]_D^{25} = +64.3$ (c 0.94, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 16.58$ min, 35.59 min.



Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(4-bromophenyl)-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate


2,8-dicarboxylate

Yield (77%); White solid, m.p: 58-60 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.49-7.47 (m, 2H), 7.43-7.40 (m, 2H), 7.37-7.33 (m, 1H), 7.26-7.21 (m, 4H), 4.43 (s, 1H), 4.28 (d, *J* = 5.7, 1H), 4.08 (d, *J* = 5.8, 1H), 3.81 (s, 3H), 3.77 (s, 3H), 2.47 (d, *J* = 18.6, 1H), 2.30 (d, *J* = 18.7, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 175.1, 172.3, 169.6, 147.6, 139.0, 133.6, 132.3, 129.5, 128.6, 128.3, 128.3, 123.3, 73.8, 67.1, 60.1, 54.9, 54.8, 52.7, 37.3; HRMS (EI, m/z): Calcd for C₂₃H₂₁BrN₂O₆ [M]⁺: 500.0578, found: 500.0584; [α]_D²⁵ = +51.1 (*c* 1.12, CH₂Cl₂); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) t_R = 25.10 min, 42.67 min.



Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(4-fluorophenyl)-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate


Yield (72%); White solid, m.p: 53-55 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.42 (m, 2H), 7.37-7.31 (m, 3H), 7.27-7.25 (m, 2H), 7.06-7.02 (m, 2H), 4.45 (s, 1H), 4.28 (d, *J* = 5.7, 1H), 4.08 (d, *J* = 5.7, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 2.47 (d, *J* = 18.6, 1H), 2.30 (d, *J* = 18.6, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 175.3, 172.3, 169.7, 163.2 (d, *J*_{C-F} = 248.5), 147.6, 139.1, 130.2 (d, *J*_{C-F} = 3.3), 129.5, 128.6, 128.4 (d, *J*_{C-F} = 8.3), 128.2, 116.1 (d, *J*_{C-F} = 21.6), 73.8, 67.2, 60.1, 55.0, 54.7, 52.7, 37.3; HRMS (EI, m/z): Calcd for C₂₃H₂₁FN₂O₆ [M]⁺: 440.1379, found: 440.1385; [α]_D²⁵ = +49.8 (*c* 1.35, CH₂Cl₂); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) t_R = 19.78 min, 35.70 min.



Dimethyl (5*R*,6*R*,8*R*,9*R*)-1,3-dioxo-9-phenyl-6-(4-(trifluoromethyl)phenyl)-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate:


Yield (82%); White solid, m.p: 54-56 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, *J* = 8.1, 2H), 7.49 (d, *J* = 8.1, 2H), 7.43 (t, *J* = 7.4, 2H), 7.36 (t, *J* = 7.2, 1H), 7.26 (d, *J* = 6.4, 2H), 4.55 (s, 1H), 4.31 (d, *J* = 5.8, 1H), 4.11 (d, *J* = 5.8, 1H), 3.82 (s, 3H), 3.70 (s, 3H), 2.50 (d, *J* = 18.7, 1H), 2.36 (d, *J* = 18.7, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 174.9, 172.3, 169.5, 147.5, 138.9, 138.8, 131.4

(q, $J_{C-F} = 32.7$), 129.6, 128.6, 128.3, 127.1, 126.1 (q, $J_{C-F} = 3.6$), 123.8 (q, $J_{C-F} = 272.1$), 73.8, 67.1, 60.4, 54.7, 54.7, 52.8, 37.5; HRMS (EI, m/z): Calcd for $C_{24}H_{21}F_3N_2O_6$ [M]⁺: 490.1347, found: 490.1354; $[\alpha]_D^{25} = +50.9$ (c 1.70, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 15.47$ min, 29.13 min.




Dimethyl (5*R*,6*R*,8*R*,9*R*)-1,3-dioxo-9-phenyl-6-(*o*-tolyl)-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (71%); White solid, m.p: 45-47 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 7.52-7.48 (m, 1H), 7.43-7.40 (m, 2H), 7.37-7.33 (m, 1H), 7.28 (d, $J = 8.5$, 2H), 7.24-7.14 (m, 3H), 4.89 (s, 1H), 4.31 (d, $J = 6.3$, 1H), 4.14 (d, $J = 6.3$, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 2.45 (d, $J = 18.4$, 1H), 2.37 (s, 3H), 2.34 (d, $J = 18.4$, 1H); ¹³C NMR (100 MHz, $CDCl_3$) δ 175.5, 172.4, 169.7, 147.7, 138.7, 135.7, 133.0, 131.4, 129.4, 128.6, 128.6, 128.2, 126.8, 126.3, 69.0, 66.7, 61.2, 55.2, 54.5, 52.7, 37.6, 20.1; HRMS (EI, m/z): Calcd for $C_{24}H_{24}N_2O_6$ [M]⁺: 436.1629, found: 436.1638; $[\alpha]_D^{25} = +19.3$ (c 1.17, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 254 nm) $t_R = 15.64$ min, 27.51 min.




Dimethyl (5*R*,6*R*,8*R*,9*R*)-1,3-dioxo-9-phenyl-6-(*p*-tolyl)-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (77%); White solid, m.p: 53-55 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 7.44-7.40 (m, 2H), 7.37-7.33 (m, 1H), 7.26 (d, $J = 7.1$, 2H), 7.19 (d, $J = 8.1$, 2H), 7.14 (d, $J = 8.1$, 2H), 4.41 (s, 1H), 4.28 (d, $J = 5.5$, 1H), 4.04 (d, $J = 5.6$, 1H), 3.82 (s, 3H), 3.75 (s, 3H), 2.43 (d, $J = 18.7$, 1H), 2.32 (s, 3H), 2.30 (d, $J = 18.6$, 1H); ¹³C NMR (100 MHz, $CDCl_3$) δ 175.6, 172.4, 169.9, 147.7, 139.4, 139.2, 130.9, 129.8, 129.4, 128.6, 128.1, 126.4, 74.4, 67.5, 60.2, 55.4, 54.5, 52.7, 37.2, 21.2; HRMS (EI, m/z): Calcd for $C_{24}H_{24}N_2O_6$ [M]⁺: 436.1629, found: 436.1633; $[\alpha]_D^{25} = +56.2$ (c 1.28, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 17.08$ min, 29.70 min.




Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(4-methoxyphenyl)-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (74%); White solid, m.p: 92-94 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.42 (t, $J = 7.3$, 2H), 7.37-7.33 (m, 1H), 7.27-7.23 (m, 4H), 6.86 (d, $J = 8.7$, 2H), 4.40 (s, 1H), 4.28 (d, $J = 5.5$, 1H), 4.05 (d, $J = 5.6$, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.76 (s, 3H), 2.44 (d, $J = 18.6$, 1H), 2.28 (d, $J = 18.7$, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.7, 172.4, 169.9, 160.3, 147.7, 139.4, 129.4, 128.6, 128.1, 127.8, 125.9, 114.5, 74.2, 67.4, 60.1, 55.3, 55.3, 54.6, 52.7, 37.2; HRMS (EI, m/z): Calcd for $\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_7$ [M] $^+$: 452.1579, found: 436.1581; $[\alpha]_D^{25} = +53.3$ (c 1.06, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 23.00$ min, 48.21 min.




Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(naphthalen-2-yl)-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (74%); White solid, m.p: 51-53 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.82 (s, 4H), 7.49-7.36 (m, 6H), 7.30-7.26 (m, 2H), 4.63 (d, $J = 6.9$, 1H), 4.35 (s, 1H), 4.12 (d, $J = 4.5$, 1H), 3.85 (s, 3H), 3.52 (brs, 1H), 3.42 (s, 3H), 2.48 (d, $J = 18.5$, 1H), 2.41 (d, $J = 18.6$, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.5, 172.4, 169.7, 147.5, 139.3, 133.7, 133.3, 131.6, 129.5, 129.1, 128.6, 128.2, 128.2, 127.7, 126.6, 126.6, 126.1, 123.9, 74.7, 67.5, 60.5, 55.1, 54.3, 52.7, 37.4; HRMS (EI, m/z): Calcd for $\text{C}_{27}\text{H}_{24}\text{N}_2\text{O}_6$ [M] $^+$: 472.1629, found: 472.1635; $[\alpha]_D^{25} = +51.8$ (c 1.12, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 27.41$ min, 53.78 min.




Dimethyl (5*R*,6*S*,8*R*,9*R*)-6-(furan-2-yl)-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (90%); White solid, m.p: 43-45 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.46-7.31 (m, 4H), 7.21 (d, $J = 7.3$, 2H), 6.41 (s, 1H), 6.34 (s, 1H), 4.54 (s, 1H), 4.29 (d, $J = 5.8$, 1H), 4.00 (d, $J = 5.7$, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 2.46 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.4, 171.8, 170.1, 148.4, 148.0, 143.2, 138.9, 129.5, 128.6, 128.2, 110.7, 108.5, 68.0, 67.7, 59.3, 55.7, 54.8, 52.7, 36.9; HRMS (EI, m/z): Calcd for $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_7$ [M] $^+$: 412.1266, found: 412.1273; $[\alpha]_D^{25} = +63.4$ (c 1.56, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 16.72$ min, 27.47 min.



Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-cyclohexyl-1,3-dioxo-9-phenyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate


Yield (40%); White solid, m.p: 85-87 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.37 (t, $J = 7.3$, 2H), 7.31 (t, $J = 7.3$, 1H), 7.13 (d, $J = 7.3$, 2H), 4.06 (d, $J = 7.6$, 1H), 3.99 (s, 3H), 3.81 (d, $J = 7.8$, 1H), 3.70 (s, 3H), 3.07 (d, $J = 7.7$, 1H), 2.76 (brs, 1H), 2.48 (d, $J = 19.2$, 1H), 2.32 (d, $J = 19.2$, 1H), 2.09 (d, $J = 12.6$, 1H), 1.81-1.60 (m, 4H), 1.34-1.06 (m, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 177.0, 171.9, 170.9, 148.3, 137.9, 129.4, 128.7, 128.3, 76.0, 66.3, 59.8, 57.9, 55.2, 52.5, 39.1, 38.3, 31.8, 31.0, 26.0, 25.9, 25.8; HRMS (EI, m/z): Calcd for $\text{C}_{23}\text{H}_{28}\text{N}_2\text{O}_6$ [M] $^+$: 428.1942, found: 428.1950; $[\alpha]_D^{25} = +27.6$ (c 0.50, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 254 nm) $t_R = 15.71$ min, 34.47 min.



Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(4-chlorophenyl)-9-(4-methoxyphenyl)-1,3-dioxo-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate


Yield (77%); White solid, m.p: 75-77 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.32 (d, $J = 8.6$, 2H), 7.27 (d, $J = 8.6$, 2H), 7.16 (d, $J = 8.7$, 2H), 6.93 (d, $J = 8.7$, 2H), 4.41 (s, 1H), 4.23 (d, $J = 5.7$, 1H), 4.03 (d, $J = 5.9$, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.77 (s, 3H), 2.50 (d, $J = 18.6$, 1H), 2.31 (d, $J = 18.7$, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.2, 172.3, 169.7, 159.3, 147.6, 135.1, 133.2, 130.8, 129.7, 129.3, 128.0, 114.8, 73.6, 67.2, 60.3, 55.4, 54.7, 54.3, 52.7, 37.3; HRMS (EI, m/z): Calcd

for $C_{24}H_{23}ClN_2O_7$ [M]⁺: 486.1189, found: 486.1190; $[\alpha]_D^{25} = +36.6$ (*c* 1.05, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 23.39$ min, 42.67 min.




Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(4-chlorophenyl)-1,3-dioxo-9-(4-(trifluoromethyl)phenyl)-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (68%); White solid, m.p: 87-89 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 7.70 (d, *J* = 8.1, 2H), 7.41 (d, *J* = 8.1, 2H), 7.34 (d, *J* = 8.6, 2H), 7.28 (d, *J* = 8.5, 2H), 4.46 (s, 1H), 4.26 (d, *J* = 5.7, 1H), 4.17 (d, *J* = 5.7, 1H), 3.83 (s, 3H), 3.77 (s, 3H), 2.43 (d, *J* = 18.5, 1H), 2.34 (d, *J* = 18.5, 1H); ¹³C NMR (100 MHz, $CDCl_3$) δ 174.7, 171.9, 169.1, 147.5, 143.0, 135.4, 132.8, 130.5 (q, *J*_{C-F} = 32.8), 129.4, 129.1, 127.9, 126.44 (q, *J*_{C-F} = 3.6), 123.8 (q, *J*_{C-F} = 272.7), 73.9, 67.0, 59.9, 54.8, 54.2, 52.8, 37.3; HRMS (EI, m/z): Calcd for $C_{24}H_{20}ClF_3N_2O_6$ [M]⁺: 524.0957, found: 524.0966; $[\alpha]_D^{25} = +42.6$ (*c* 1.12, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 14.19$ min, 35.96 min.




Dimethyl (5*R*,6*R*,8*R*,9*R*)-9-(4-bromophenyl)-6-(4-chlorophenyl)-1,3-dioxo-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (88%); White solid, m.p: 85-87 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 7.55 (d, *J* = 8.2, 2H), 7.33 (d, *J* = 8.4, 2H), 7.27 (d, *J* = 8.5, 2H), 7.14 (d, *J* = 8.3, 2H), 4.41 (d, *J* = 10.0, 1H), 4.23-4.18 (m, 1H), 4.05 (d, *J* = 5.8, 1H), 3.82 (s, 3H), 3.77 (s, 3H), 3.30-3.21 (m, 1H), 2.46 (d, *J* = 18.5, 1H), 2.33 (d, *J* = 18.5, 1H); ¹³C NMR (100 MHz, $CDCl_3$) δ 174.9, 172.0, 169.3, 147.5, 137.9, 135.3, 132.9, 132.6, 130.3, 129.4, 129.4, 128.0, 122.3, 73.8, 67.1, 59.9, 54.8, 54.1, 52.8, 37.3; HRMS (EI, m/z): Calcd for $C_{23}H_{20}BrClN_2O_6$ [M]⁺: 534.0188, found: 534.0181; $[\alpha]_D^{25} = +78.9$ (*c* 1.18, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 23.87$ min, 43.44 min.




Dimethyl (*5R,6R,8R,9R*)-9-(3-bromophenyl)-6-(4-chlorophenyl)-1,3-dioxo-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (85%); White solid, m.p: 80-82 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.50 (d, $J = 8.0$, 1H), 7.42 (s, 1H), 7.35-7.25 (m, 5H), 7.20 (d, $J = 7.7$, 1H), 4.43 (d, $J = 9.7$, 1H), 4.22 (t, $J = 6.2$, 1H), 4.05 (d, $J = 5.7$, 1H), 3.83 (s, 3H), 3.76 (s, 3H), 3.33-3.20 (m, 1H), 2.48 (d, $J = 18.5$, 1H), 2.35 (d, $J = 18.5$, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.9, 172.0, 169.3, 147.5, 141.4, 135.3, 132.9, 131.6, 131.4, 131.0, 129.4, 128.0, 127.3, 123.5, 73.8, 67.1, 60.0, 54.8, 54.2, 52.8, 37.3; HRMS (EI, m/z): Calcd for $\text{C}_{23}\text{H}_{20}\text{BrClN}_2\text{O}_6$ [M] $^+$: 534.0188, found: 534.0196; $[\alpha]_D^{25} = +60.6$ (c 1.32, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 254 nm) $t_R = 54.26$ min, 59.42 min.




Dimethyl (*5R,6R,8R,9R*)-6-(4-chlorophenyl)-9-(furan-2-yl)-1,3-dioxo-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (60%); Yellow solid, m.p: 56-58 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.45 (s, 1H), 7.33 (d, $J = 8.5$, 2H), 7.27 (d, $J = 8.4$, 2H), 6.39-6.38 (m, 1H), 6.31-6.30 (m, 1H), 4.47 (s, 1H), 4.30 (d, $J = 6.0$, 1H), 4.14 (d, $J = 6.0$, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 2.49 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.9, 171.6, 169.7, 151.9, 147.6, 143.3, 135.3, 132.6, 129.3, 128.0, 110.7, 109.6, 72.8, 64.4, 59.5, 54.8, 52.8, 48.5, 36.4; HRMS (EI, m/z): Calcd for $\text{C}_{21}\text{H}_{19}\text{ClN}_2\text{O}_7$ [M] $^+$: 446.0876, found: 446.0877; $[\alpha]_D^{25} = +35.7$ (c 1.00, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) $t_R = 16.67$ min, 34.82 min.




Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(4-chlorophenyl)-1,3-dioxo-9-propyl-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (50%); White solid, m.p: 47-49 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.31 (d, *J* = 7.4, 2H), 7.25 (d, *J* = 7.4, 2H), 4.18 (s, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 3.77 (s, 1H), 3.00 (d, *J* = 18.2, 1H), 2.90-2.82 (m, 1H), 2.60 (d, *J* = 18.2, 1H), 1.61-1.30 (m, 4H), 1.09-0.88 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 175.2, 172.9, 169.9, 147.7, 135.1, 133.3, 129.2, 128.0, 72.6, 65.1, 58.8, 54.8, 52.7, 47.4, 36.0, 33.4, 20.5, 14.0; HRMS (EI, m/z): Calcd for C₂₀H₂₃ClN₂O₆ [M]⁺: 422.1240, found: 422.1246; [α]_D²⁵ = +51.7 (*c* 1.52, CH₂Cl₂); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 254 nm) t_R = 16.77 min, 35.28 min.




Dimethyl (5*R*,6*R*,8*R*,9*R*)-6-(4-chlorophenyl)-1,3-dioxo-9-((E)-styryl)-2,7-diazaspiro[4.4]nonane-2,8-dicarboxylate

Yield (30%); Yellow solid, m.p: 74-76 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.23 (m, 9H), 6.59 (d, *J* = 15.6 Hz, 1H), 6.10 (dd, *J* = 14.6, 11.0 Hz, 1H), 4.30 (s, 1H), 3.94 (d, *J* = 3.5 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 3.76 (s, 1H), 3.70-3.68 (m, 1H), 3.05 (d, *J* = 18.4 Hz, 1H), 2.61 (d, *J* = 18.3 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 174.9, 172.0, 169.7, 147.7, 135.7, 135.6, 135.2, 132.9, 129.3, 128.8, 128.5, 128.0, 126.6, 125.8, 72.8, 65.9, 59.2, 54.8, 53.2, 52.8, 36.4; HRMS (EI, m/z): Calcd for C₂₅H₂₃ClN₂O₆ [M]⁺: 482.1240, found: 482.1239; [α]_D²⁵ = +17.9 (*c* 0.62, CH₂Cl₂); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 70/30, 1.0 mL/min, 254 nm) t_R = 18.78 min, 36.62 min.



Under a nitrogen atmosphere, Cu(CH₃CN)₄BF₄ (3.1 mg, 0.01 mmol), ligand **4a** (4.4 mg, 0.011 mmol), and Et₃N (5.6 μL, 0.04 mmol) were dissolved in CH₂Cl₂ (2 mL), and stirred at room temperature for approximately 1 h. Then, iminoester **1a** (84.7 mg, 0.4 mmol) was added, the mixture was cooled to -20 °C and α-alkyldene succinimide **2k** (37.4 mg, 0.2 mmol) was then


added. Once starting material was consumed (monitored by TLC), the mixture was concentrated and purified by column chromatography to give the corresponding cycloaddition product.



Methyl (1*R*,3*R*,5*S*)-1-(4-chlorophenyl)-6,8-dioxo-7-phenyl-2,7-diazaspiro[4.4]nonane-3-carboxylate

Yield (90%); White solid, m.p: 74-76 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.37-7.28 (m, 7H), 6.62-6.56 (m, 2H), 4.28 (s, 1H), 4.15 (dd, $J = 9.9, 5.1$, 1H), 3.83 (s, 3H), 2.99 (dd, $J = 38.5, 17.1$, 2H), 2.91 (dd, $J = 12.3, 6.4$, 1H), 2.47 (dd, $J = 13.7, 9.9$, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 177.1, 172.5, 171.8, 133.9, 132.8, 130.1, 128.1, 128.0, 127.7, 127.0, 125.2, 72.1, 57.8, 53.2, 51.56, 38.2, 38.0; HRMS (EI, m/z): Calcd for $\text{C}_{21}\text{H}_{19}\text{ClN}_2\text{O}_4$ [M] $^+$: 398.1028, found: 398.1032; $[\alpha]_D^{25} = -21.8$ (c 1.25, CH_2Cl_2); HPLC (Chiralcel IF, *n*-hexane/EtOAc = 50/50, 0.8 mL/min, 254 nm) $t_R = 9.63$ min, 10.55 min.

Scheme S1. Scaled up asymmetric 1,3-dipolar cycloaddition of azomethine ylide **1f to α -alkylidene succinimide **2b****




Synthetic transformations of the cycloadduct



Compound **3fa** (100.3 mg, 0.2 mmol), CH₂Cl₂(5 mL), triethylamine (27.9 μ L, 0.2 mmol) and benzylamine (24.1 μ L, 0.22 mmol) were placed in a 10 mL round-bottom flask with magnetic stir bar at room temperature. The resulting mixture was allowed to stir for 24 h. Then, the solvent was removed *in vacuo* and the residue was purified by column chromatography to give **6**.

Methyl (1*R*,3*R*,4*R*,5*R*)-1-(4-bromophenyl)-6,8-dioxo-4-phenyl-2,7-diazaspiro[4.4]nonane-

3-carboxylate (6): Yield (85%); White solid, m.p: 95-97 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.68 (brs, 1H), 7.48-7.38 (m, 4H), 7.38-7.32 (m, 1H), 7.26-7.19 (m, 4H), 4.38 (s, 1H), 4.23 (d, J = 6.2, 1H), 4.02 (d, J = 6.2, 1H), 3.79 (s, 3H), 3.29 (brs, 1H), 2.43 (d, J = 18.7, 1H), 2.27 (d, J = 18.7, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 178.4, 173.3, 171.3, 138.0, 133.3, 131.1, 128.4, 127.6, 127.4, 127.1, 122.0, 71.9, 65.9, 59.9, 54.2, 51.6, 36.8; HRMS (EI, m/z): Calcd for $\text{C}_{21}\text{H}_{19}\text{BrN}_2\text{O}_4$ [M] $^+$: 442.0523, found: 442.0526; $[\alpha]_{\text{D}}^{25} = +64.7$ (c 1.33, CH_2Cl_2); HPLC (Chiralcel AD-H, *n*-hexane/i-propanol = 70/30, 1.0 mL/min, 254 nm) $t_{\text{R}} = 14.43$ min, 15.09 min.




To a solution of **6** (88.7 mg, 0.2 mmol) and K₂CO₃ (165.9 mg, 1.2 mmol) in DMF (2 mL) MeI (37.5 µL, 0.6 mmol) was added at room temperature. The mixture was stirred for 4 h and was then quenched with water, the aqueous phase was extracted with CH₂Cl₂. The combined organic phases were dried over anhydrous Na₂SO₄. The solvent was removed *in vacuo* and the residue was purified by column chromatography to afford **7**.

Methyl **(1*R*,3*R*,4*R*,5*R*)-1-(4-bromophenyl)-2,7-dimethyl-6,8-dioxo-4-phenyl-2,7-diazaspiro**

[4.4]nonane-3-carboxylate (7): Yield (92%); White solid, m.p: 131-133 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J* = 8.5, 2H), 7.41-7.34 (m, 2H), 7.34-7.28 (m, 3H), 7.17-7.15 (m, 2H), 4.27 (d, *J* = 7.9, 1H), 3.76 (s, 1H), 3.73 (s, 1H), 3.65 (d, *J* = 7.9, 1H), 2.45 (s, 3H), 2.36 (s, 3H), 2.33 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 177.0, 173.2, 170.8, 137.2, 134.2, 130.8, 128.3, 128.2, 127.9, 127.0, 121.8, 79.8, 72.5, 58.1, 51.3, 50.7, 38.3, 37.4, 23.3. HRMS (EI, m/z): Calcd for

$C_{23}H_{23}BrN_2O_4[M]^+$: 470.0836, found: 470.0849; $[\alpha]_D^{25} = +43.0$ (c 1.50, CH_2Cl_2).



Compound **7** (94.2 mg, 0.2 mmol) was dissolved in dry THF (4 mL) at 0 °C under a nitrogen atmosphere. Lithium aluminium hydride (60.7 mg, 1.6 mmol) was added in portions. Cooling was removed and the mixture was heated at reflux for 48 h protected from air. The mixture was cooled to 0 °C and the following were slowly added dropwise: water (0.1 mL), 15% NaOH aq (0.1 mL) and water (0.3 mL). The resulting slurry was filtered, the solids were washed with THF (10 mL) and the combined filtrates were concentrated *in vacuo* and the residue was purified by column chromatography to afford **8**.

((1*R*,3*R*,4*R*,5*S*)-2,7-dimethyl-1,4-diphenyl-2,7-diazaspiro[4.4]nonan-3-yl)methanol (8): Yield (65%), Colorless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.41-7.17 (m, 10H), 3.80 (dd, $J = 11.1, 3.6, 1\text{H}$), 3.67 (s, 1H), 3.52 (dd, $J = 11.1, 1.5, 1\text{H}$), 3.41 (d, $J = 7.7, 1\text{H}$), 2.93 (ddd, $J = 7.6, 3.5, 1.5, 1\text{H}$), 2.86 (brs, 1H), 2.61 (d, $J = 9.3, 1\text{H}$), 2.27 (s, 3H), 2.17-2.08 (m, 2H), 2.04 (s, 3H), 1.86 (td, $J = 8.7, 5.8, 1\text{H}$), 1.57-1.42 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.3, 138.2, 129.0, 127.9, 127.2, 127.1, 126.4, 125.5, 78.8, 71.7, 64.1, 59.1, 56.2, 54.9, 53.0, 41.3, 38.3, 31.1. HRMS (EI, m/z): Calcd for $\text{C}_{22}\text{H}_{28}\text{N}_2\text{O} [\text{M}]^+$: 336.2197, found: 336.2206; $[\alpha]_D^{25} = -35.2$ (c 1.20, CH_2Cl_2); HPLC (Chiralcel AS-H, *n*-hexane/*i*-propanol = 90/10, 0.8 mL/min, 254 nm) $t_{\text{R}} = 5.24$ min, 12.39 min.

The absolute configuration determination of (*1R,3R,4R,5R*)-6





Fig S1. X-ray structure of (*1R,3R,4R,5R*)-6

Crystal data and structure refinement for cd21432

(CCDC 1019642 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge *via* www.ccdc.cam.ac.uk/conts/retrieving.html.)


Empirical formula	C ₂₂ H ₁₉ BrCl ₃ N ₂ O ₄
Formula weight	561.65
Temperature	293(2) K
Crystal system, space group	Orthorhombic, P2(1)2(1)2(1)
Unit cell dimensions	a = 10.2175(12) Å; b = 12.1386(14) Å; c = 19.641(2) Å
Volume	2436.0(5) Å ³
Z, Calculated density	4, 1.531 Mg/m ³
Reflections collected / unique	14495 / 3494 [R (int) = 0.0401]
Refinement method	Full-matrix least-squares on F ²
Final R indices [I>2 sigma(I)]	R1 = 0.0638, wR2 = 0.1817
R indices (all data)	R1 = 0.0877, wR2 = 0.1980

Scheme S2. Proposed transition state leading to the major product *endo*-3ab




The excellent diastereoselectivities and enantioselectivities observed in this 1,3-dipolar cycloaddition can be rationalised by considering the proposed transition state **I** shown in Scheme S2. According to a previous report,⁴ the 1,3-dipolar cycloaddition is proposed to favor an *endo* cycloaddition mode, and two phenyl groups adjacent to the oxygen in the ligand might block the dipolarophile's approach from the “bottom” face (as drawn) and form *endo*-(5*R*,6*R*,8*R*,9*R*)-**3ab** through approach from the “top” face.

Procedure for the asymmetric 1,3-dipolar cycloaddition of azomethine ylides to 2-oxoindolin-3-ylidenes




Under a nitrogen atmosphere, **Cu(OAc)₂·H₂O** (2.0 mg, 0.01 mmol), ligand **4a** (4.4 mg, 0.011 mmol), DIPEA (3.3 µL, 0.02 mmol) and 4 Å MS were dissolved in CPME (1 mL), and stirred at room temperature for approximately 1 h. Next, iminoester **1** (0.2 mmol) and 2-oxoindolin-3-ylidene **9** (0.1 mmol) were added sequentially. Once starting material was consumed (monitored by TLC), the mixture was concentrated and purified by column chromatography to give the corresponding cycloaddition product **10**.




Methyl (2'R,3S,4'R,5'R)-2'-(4-chlorophenyl)-2-oxo-4'-phenylspiro[indoline-3,3'-pyrrolidine]-5'-carboxylate

Yield (95%); ^1H NMR (400 MHz, CDCl_3) δ 7.34-7.28 (m, 3H), 7.23-7.20 (m, 2H), 7.11-7.07 (m, 2H), 7.03 (td, $J = 7.7, 1.1, 1\text{H}$), 6.97 (s, 1H), 6.90 (d, $J = 8.5, 2\text{H}$), 6.68 (td, $J = 7.7, 0.9, 1\text{H}$), 6.57 (d, $J = 7.7, 1\text{H}$), 6.04 (d, $J = 7.6, 1\text{H}$), 4.69 (s, 1H), 4.58 (d, $J = 4.8, 1\text{H}$), 4.18 (d, $J = 5.0, 1\text{H}$), 3.84 (s, 3H); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 254 nm) $t_{\text{R}} = 13.42$ min, 17.84 min. $[\alpha]_D^{25} = +132.6$ (c 1.00, CHCl_3). The absolute stereochemistry was determined by comparing optical rotations with literature report ($[\alpha]_D^{25} = +153.3$ (c 1.00, CHCl_3), 91% ee).^{5,6}




Methyl (2'R,3S,4'R,5'R)-2-oxo-2',4'-diphenylspiro[indoline-3,3'-pyrrolidine]-5'-carboxylate

Yield (95%); ^1H NMR (400 MHz, CDCl_3) δ 7.34-7.27 (m, 4H), 7.25-7.20 (m, 2H), 7.17-7.06 (m, 3H), 7.02 (t, $J = 7.7, 1\text{H}$), 6.95 (d, $J = 7.4, 2\text{H}$), 6.68 (t, $J = 7.6, 1\text{H}$), 6.55 (d, $J = 7.7, 1\text{H}$), 6.06 (d, $J = 7.6, 1\text{H}$), 4.72 (s, 1H), 4.59 (d, $J = 4.1, 1\text{H}$), 4.18 (d, $J = 5.0, 1\text{H}$), 3.84 (s, 3H), 3.74 (brs, 1H); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 90/10, 1.0 mL/min, 254 nm) $t_{\text{R}} = 23.51$ min, 27.16 min.




Methyl (2'R,3S,4'R,5'R)-2'-(4-bromophenyl)-2-oxo-4'-phenylspiro[indoline-3,3'-pyrrolidine]-5'-carboxylate

Yield (93%); ^1H NMR (400 MHz, CDCl_3) δ 7.35-7.27 (m, 3H), 7.25-7.15 (m, 4H), 7.04 (t, $J = 7.6, 1\text{H}$), 6.84 (d, $J = 8.4, 2\text{H}$), 6.68 (t, $J = 7.6, 1\text{H}$), 6.58 (d, $J = 7.8 \text{ Hz}, 1\text{H}$), 6.08-6.00 (m, 1H), 4.67 (s, 1H), 4.58 (d, $J = 4.8, 1\text{H}$), 4.17 (d, $J = 4.9, 1\text{H}$), 3.84 (s, 3H), 3.65 (brs, 1H). HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 90/10, 1.0 mL/min, 254 nm) $t_{\text{R}} = 28.96$ min, 40.40 min.




Methyl (2'R,3S,4'R,5'R)-2'-(4-fluorophenyl)-2-oxo-4'-phenylspiro[indoline-3,3'-pyrrolidine]-5'-carboxylate

Yield (99%); ^1H NMR (400 MHz, CDCl_3) δ 7.35-7.27 (m, 3H), 7.24-7.20 (m, 2H), 7.13 (s, 1H), 7.03 (td, $J = 7.7, 0.9$, 1H), 6.98-6.90 (m, 2H), 6.80 (t, $J = 8.7$, 2H), 6.68 (td, $J = 7.6, 0.7$, 1H), 6.57 (d, $J = 7.7$, 1H), 6.03 (d, $J = 7.6$, 1H), 4.70 (s, 1H), 4.58 (d, $J = 4.6$, 1H), 4.18 (d, $J = 4.8$, 1H), 3.84 (s, 3H), 3.66 (brs, 1H); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 90/10, 1.0 mL/min, 254 nm) t_R = 23.33 min, 28.32 min.



Methyl (2'R,3S,4'R,5'R)-2',4'-bis(4-chlorophenyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxylate

Yield (95%); ^1H NMR (400 MHz, CDCl_3) δ 7.35 (s, 1H), 7.27 (d, $J = 5.9$, 2H), 7.16-7.05 (m, 5H), 6.90 (d, $J = 8.2$, 2H), 6.78 (t, $J = 7.6$, 1H), 6.60 (d, $J = 7.8$, 1H), 6.23 (d, $J = 7.5$, 1H), 4.65 (s, 1H), 4.52 (d, $J = 4.7$, 1H), 4.13 (d, $J = 5.5$, 1H), 3.83 (s, 3H), 3.58 (brs, 1H); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 90/10, 1.0 mL/min, 254 nm) t_R = 26.06 min, 32.18 min.




Methyl (2'R,3S,4'R,5'R)-2'-(4-chlorophenyl)-2-oxo-4'-(*p*-tolyl)spiro[indoline-3,3'-pyrrolidine]-5'-carboxylate


Yield (88%); ^1H NMR (400 MHz, CDCl_3) δ 7.20 (s, 1H), 7.13-7.02 (m, 7H), 6.89 (d, $J = 8.4$, 2H), 6.71 (t, $J = 7.6$, 1H), 6.57 (d, $J = 7.7$, 1H), 6.12 (d, $J = 7.6$, 1H), 4.68 (d, $J = 8.0$, 1H), 4.55 (s, 1H), 4.13 (d, $J = 5.0$, 1H), 3.83 (s, 3H), 2.34 (s, 3H), 3.64 (brs, 1H); HPLC (Chiralcel AD-H, *n*-hexane/*i*-propanol = 90/10, 1.0 mL/min, 254 nm) t_R = 19.48 min, 31.16 min.

References



1. J. Wang, H. Liu, Y. Fan, Y. Yang, Z. Jiang and C.-H. Tan, *Chem. Eur. J.*, 2010, **16**, 12534.
2. Y. Liu, W. Zhang, *Angew. Chem., Int. Ed.*, 2013, **52**, 2203.
3. Y. Luo, L. Ma, H. Zheng, L. Chen, R. Li, C. He, S. Yang, X. Ye, Z. Chen, Z. Li, Y. Gao, J. Han, G. He, L. Yang and Y. Wei, *J. Med. Chem.*, 2010, **53**, 273.
4. M. Wang, Z. Wang, Y.-H. Shi, X.-X. Shi, J. S. Fossey and W.-P. Deng, *Angew. Chem., Int. Ed.*, 2011, **50**, 4897.
5. A. P. Antonchick, C. Gerdin-Reimers, M. Catarinella, M. Schürmann, H. Preut, S. Ziegler, D. Rauh and H. Waldmann, *Nat. Chem.*, 2010, **2**, 735.
6. T.-L. Liu, Z.-Y. Xue, H.-Y. Tao and C.-J. Wang, *Org. Biomol. Chem.*, 2011, **9**, 1980.

Chiral HPLC Chromatograms








#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	21.23333	10.31	438.03	2.3783
2	34.28000	109.13	17980.00	97.6217






#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	18.37500	148.01	5730.43	51.8077
2	40.11333	34.55	5330.52	48.1923




#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	18.57000	11.89	509.97	3.9301
2	38.30167	73.18	12466.00	96.0699





#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	18.81167	28.85	1093.41	49.7038
2	30.21333	18.44	1106.45	50.2962









#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	17.16250	11.51	345.16	3.1303
2	22.62583	134.16	10681.18	96.8697





#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	16.12083	52.84	1602.91	49.8293
2	34.62333	23.37	1613.89	50.1707














#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	25.10458	6.55	328.95	2.4632
2	42.67417	66.42	13025.50	97.5368






#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	19.21500	57.04	2055.64	50.2915
2	36.08417	24.91	2031.81	49.7085













#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	23.43333	184.86	8774.66	49.4868
2	51.67667	35.86	8956.67	50.5132





#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	22.99917	11.99	569.50	2.4110
2	48.20583	87.62	23051.68	97.5890






#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	26.68083	314.30	16221.89	49.9088
2	52.18083	123.76	16281.16	50.0912







#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	27.41417	11.17	585.62	2.7222
2	53.75750	149.12	20926.84	97.2778





#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	15.66917	83.38	2562.53	49.8880
2	25.76917	54.54	2574.03	50.1120
















#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	23.39167	6.60	343.82	2.5985
2	42.66583	124.67	12887.57	97.4015







#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	13.14583	297.45	8701.88	49.8960
2	33.55917	81.54	8738.16	50.1040
















#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	16.76750	6.61	248.32	2.8667
2	35.27750	91.61	8413.68	97.1333






#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	19.76583	588.45	22823.82	48.6902
2	38.33583	294.42	24051.73	51.3098









#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	18.78167	38.66	1381.95	6.7092
2	36.62000	247.30	19215.96	93.2908









#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	9.88250	264.58	4521.86	47.7510
2	11.37167	219.78	4947.80	52.2490

























#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	23.32750	10.22	647.03	3.1471
2	28.32417	329.72	19912.41	96.8529




#	Ret Time(min)	Height(mV)	Area(mV.sec)	Area (%)
1	23.43500	34.59	1834.84	49.5794
2	29.22417	30.28	1865.97	50.4206






¹H NMR and ¹³C NMR spectra


¹H NMR spectrum of compound **3ab** (CDCl_3)




¹³C NMR spectrum of compound **3ab** (CDCl_3)




¹H NMR spectrum of compound **3bb** (CDCl_3)




¹³C NMR spectrum of compound **3bb** (CDCl_3)




¹H NMR spectrum of compound **3cb** (CDCl_3)




¹³C NMR spectrum of compound **3cb** (CDCl_3)




¹H NMR spectrum of compound **3db** (CDCl_3)





¹³C NMR spectrum of compound **3db** (CDCl_3)





¹H NMR spectrum of compound **3eb** (CDCl_3)




¹³C NMR spectrum of compound **3eb** (CDCl_3)




¹³C NMR spectrum of compound **3fb** (CDCl_3)




^{13}C NMR spectrum of compound **3gb** (CDCl_3)




^1H NMR spectrum of compound **3hb** (CDCl_3)




^{13}C NMR spectrum of compound **3hb** (CDCl_3)




¹H NMR spectrum of compound **3ib** (CDCl₃)




¹³C NMR spectrum of compound **3ib** (CDCl₃)




¹H NMR spectrum of compound **3jb** (CDCl_3)




¹³C NMR spectrum of compound **3jb** (CDCl_3)




¹H NMR spectrum of compound **3kb** (CDCl_3)




¹³C NMR spectrum of compound **3kb** (CDCl_3)




¹H NMR spectrum of compound **3lb** (CDCl₃)




¹³C NMR spectrum of compound **3lb** (CDCl₃)




¹H NMR spectrum of compound **3mb** (CDCl_3)




¹³C NMR spectrum of compound **3mb** (CDCl_3)




¹H NMR spectrum of compound **3nb** (CDCl₃)




¹³C NMR spectrum of compound **3nb** (CDCl₃)




¹H NMR spectrum of compound **3ad** (CDCl_3)




¹³C NMR spectrum of compound **3ad** (CDCl_3)




¹H NMR spectrum of compound **3ae** (CDCl_3)




¹³C NMR spectrum of compound **3ae** (CDCl_3)




¹H NMR spectrum of compound 3af (CDCl_3)




¹³C NMR spectrum of compound 3af (CDCl_3)




^1H NMR spectrum of compound **3ag** (CDCl_3)




^{13}C NMR spectrum of compound **3ag** (CDCl_3)




^1H NMR spectrum of compound **3ah** (CDCl_3)




^{13}C NMR spectrum of compound **3ah** (CDCl_3)




¹H NMR spectrum of compound 3ai (CDCl_3)





¹³C NMR spectrum of compound 3ai (CDCl_3)




¹H NMR spectrum of compound 3aj (CDCl_3)







¹³C NMR spectrum of compound **3ak** (CDCl_3)




^1H NMR spectrum of compound **6** (CDCl_3)




^{13}C NMR spectrum of compound **6** (CDCl_3)




¹H NMR spectrum of compound 7 (CDCl₃)



¹³C NMR spectrum of compound 7 (CDCl₃)



¹H NMR spectrum of compound **8** (CDCl₃)



¹³C NMR spectrum of compound **8** (CDCl_3)

